Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the value judgments that are always incorporated into payers’ and health systems’ assessments of the clinical- and cost-effectiveness of interventions and into their discussions whether to adopt them.
No takes yet. Share an insight, caveat, or question.
M. D. Rawlins (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: